Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.
2021
We welcome Drs. Foer and Cahill sharing their recent findings (1,2) on the association of glucagon-like peptide 1 receptor agonists with fewer respiratory disease exacerbations and providing their perspective on our study (3).
One of the main challenges researchers encounter when conducting comparative effectiveness studies of glucose-lowering agents is selecting the most appropriate comparator (4 …
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
4
References
0
Citations
NaN
KQI